Literature DB >> 35788886

Diagnostic and prognostic value of Stanniocalcin 1 expression in papillary thyroid cancer.

Sevinç Sengun1, Hakan Korkmaz2, Metin Ciris3, Ramazan Oguz Yüceer3, Serife Mehtap Boyluboy4, Mehmet Kiran3.   

Abstract

PURPOSE: To evaluate the potential role of immunohistochemical changes in stanniocalcin 1 (STC1) and stanniocalcin 2 (STC2) expressions in papillary thyroid cancer (PTC) tissues in the disease's diagnosis and to investigate their relationship with classical clinicopathological prognostic factors.
METHODS: The study included 100 patients with PTC. Normal thyroid tissue adjacent to the tumor was taken as the control group. Clinicopathological prognostic features at the time of diagnosis of patients were recorded. STC1 and STC2 expressions of tumor tissue and adjacent normal tissue were determined immunohistochemically.
RESULTS: The sensitivity of STC1 in the diagnosis of PTC was 93%, the specificity was 94%, positive predictive value (PPV) 93.9%, and negative predictive value (NPV) 93.1%. It was determined that the STC1 staining score in tumor tissue was positively correlated with the disease TNM stage score (r = 0.259, p = 0.009) and the increase in STC1 staining score were independent risk factors that increased the risk of lymph node metastasis (R2 = 0.398, p < 0.001). While 21% of the tumor tissues were stained with STC2, none of the normal thyroid tissues adjacent to the tumor tissue showed any staining with STC2. No correlation was found between STC2 immunohistochemical staining of tumor tissue and clinicopathological risk factors for the disease.
CONCLUSION: Increased STC1 expression in thyroid lesions may be helpful in diagnosing PTC. In addition, since increased STC1 expression in PTC tissues is associated with the risk of lymph node metastasis, it may be an efficient marker for predicting the prognosis of the disease.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Diagnosis; Papillary thyroid cancer; Prognosis; STC1; STC2

Mesh:

Substances:

Year:  2022        PMID: 35788886     DOI: 10.1007/s12020-022-03126-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  39 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  The immunohistochemical localization of S100 in the diagnosis of papillary carcinoma of the thyroid.

Authors:  K M McLaren; D W Cossar
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

Review 4.  Application of immunohistochemistry in thyroid pathology.

Authors:  Haiyan Liu; Fan Lin
Journal:  Arch Pathol Lab Med       Date:  2015-01       Impact factor: 5.534

Review 5.  Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee.

Authors:  Laurence Leenhardt; Pascale Grosclaude; Laurence Chérié-Challine
Journal:  Thyroid       Date:  2004-12       Impact factor: 6.568

6.  Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.

Authors:  M Miettinen; A J Kovatich; P Kärkkäinen
Journal:  Virchows Arch       Date:  1997-12       Impact factor: 4.064

7.  An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types.

Authors:  Y Yamamoto; K Izumi; H Otsuka
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

8.  Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference.

Authors:  Zubair W Baloch; Virginia A LiVolsi; Syl L Asa; Juan Rosai; Maria J Merino; Gregory Randolph; Philippe Vielh; Richard M DeMay; Mary K Sidawy; William J Frable
Journal:  Diagn Cytopathol       Date:  2008-06       Impact factor: 1.582

9.  Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze.

Authors:  Hatice Toy; Ozlem Etli; Zeliha Esin Celik; Arsenal Sezgin Alikanoglu
Journal:  Pathol Oncol Res       Date:  2017-11-17       Impact factor: 3.201

10.  Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis.

Authors:  Xingkai Liu; Chang Su; Jing Xu; Dan Zhou; He Yan; Wei Li; Guihui Chen; Nan Zhang; Dahai Xu; Haixia Hu
Journal:  Oncol Lett       Date:  2018-12-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.